- Home
- APGE
as 04-18-2025 1:30pm EST
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.1B | IPO Year: | 2023 |
| Target Price: | $91.33 | AVG Volume (30 days): | 802.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $26.20 - $63.50 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 743.14% |
Stock Insider Trading Activity of Apogee Therapeutics Inc. (APGE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dambkowski Carl | APGE | Chief Medical Officer | Apr 2 '25 | Sell | $36.73 | 3,860 | $139,801.27 | 248,562 | |
| Dambkowski Carl | APGE | Chief Medical Officer | Mar 5 '25 | Sell | $30.48 | 1,590 | $48,463.20 | 248,562 | |
| HENDERSON MICHAEL THOMAS | APGE | Chief Executive Officer | Mar 5 '25 | Sell | $30.30 | 10,000 | $301,511.36 | 1,292,987 | |
| Dambkowski Carl | APGE | Chief Medical Officer | Feb 5 '25 | Sell | $40.69 | 3,520 | $143,228.80 | 248,562 | |
| HENDERSON MICHAEL THOMAS | APGE | Chief Executive Officer | Feb 5 '25 | Sell | $40.58 | 15,000 | $608,700.00 | 1,292,987 |
Latest Apogee Therapeutics Inc. News
APGE Breaking Stock News: Dive into APGE Ticker-Specific Updates for Smart Investing
Insider Monkey
24 days ago
Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025?
MT Newswires
a month ago
Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target
Benzinga
2 months ago
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial
MT Newswires
2 months ago
Apogee Therapeutics Full-Year Loss Widens
GlobeNewswire
2 months ago
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
GlobeNewswire
2 months ago
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Insider Monkey
2 months ago
Is Apogee Therapeutics, Inc. (APGE) the Best Small-Cap Stock to Buy Now?
GlobeNewswire
2 months ago
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025
Compare APGE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APGE Apogee Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.